Clinical outcome of Er:YAG and Nd:YAG combination laser treatment for Meibomian gland dysfunction in patients with baggy eyelid

Phase 2

Completed

• Conditions: Meibomian Gland Disease; Meibomian gland disease; MGD; Dry eye

• Registration Number: TCTR20200410011
• Lead Sponsor: Bumrungrad International Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-11-01
• Study Start: 2020-04-10
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

1.Age more than or equal to 18 years
2. Clinially diagnosed with any stage of MGD with OSDI more than 12 or meibum quality score more than 1

Exclusion Criteria

1)Blindness or having one eye
2)Having a history of glaucoma which required topical anti-glaucoma treatment
3)Having a history of glaucoma and retinal intraocular surgery or lid surgery
4)Having a history of ocular herpes within prior 3 months
5)Having an active ocular inflammation or infection
6)Having eyelid or ocular surface diseases
7)Having systemic disease(s) causing dry eye / delayed wound healing
8)Contact lens wearer
9)Having abnormal scarring at laser treatment site
10)Infection or inflammation of treatment area
11)Prone to excessive sunlight exposure (tanned skin), which was darker than natural skin face tone within 2 weeks after the procedure [eg., outdoor occupation (farming, aerobic trainer), outdoor sport player, regular beach goers, etc.]
12)Having a history of photosensitivity or use of photosensitizing medication
13)Being pregnancy
14)Having uncontrolled diabetes, heart and lung disease, or hypertension
15)Known of cancer in the area to be treated
16)Having autoimmune disorder(s)
17)Having herpes simplex infection in the treatment area
18)Having collagen, scarring and connective tissue disorders
19)Having clotting disorders
20)Having wound healing disorders
21)Having or known of Epilepsy
22)Having used Retin-A or similar products 3 days before and 7 days after treatment
23)Having used Accutane (Roaccutane) within 6 months
24)Having used Systemic antifungal, oral antifungal therapy, or isotretinoin within 6 months
25)Ever used Gold therapy

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Meibum quality score baseline, at 16-20 week, at 24-28week follow-up Meibum quality was assessed after force was applied to the eyelids via the Meibomian Gland Evaluator